Form 8.3 - AXA INVESTMENT MANAGERS: Spirent Communications plc
May 09, 2024 05:38 ET
|
AXA Investment Managers SA
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE / DEALING BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY...
Global Outdoor Furniture Business Analysis Report 2024-2030: Innovations Blur the Difference between Outdoor and Indoor Furniture, Innovative Weather Resistant Materials & Fabrics Fuel Demand
May 09, 2024 05:35 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Outdoor Furniture - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Outdoor Furniture Market to...
Global Antimicrobial Coatings Industry Research 2024-2030: A Powerful Solution for Biomedical Applications, Spiraling Popularity for Medical Devices, Revival in Construction Spurs Growth
May 09, 2024 05:23 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Antimicrobial Coatings - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Antimicrobial Coatings...
Himax Technologies, Inc. Reports First Quarter 2024 Financial Results; Provides Second Quarter 2024 Guidance
May 09, 2024 05:20 ET
|
Himax Technologies, Inc.
Q1 2024 Revenues, EPS and Gross Margin All Exceeded Guidance Range Issued on February 6, 2024Company Q2 2024 Guidance: Revenues to Increase 8% to 13% QoQ,Gross Margin is Expected to be 31.5% to 33.5%,...
Lixiang Education Received Notice of Failure to Satisfy Continued Listing Rule
May 09, 2024 05:20 ET
|
Lixiang Education Holding Co., Ltd.
LISHUI, China, May 09, 2024 (GLOBE NEWSWIRE) -- Lixiang Education Holding Co., Ltd. (the “Company” or NASDAQ: LXEH), a prestigious private education service provider in China, today announced that...
Global Ethylene Industry Report 2024-2030 Featuring SINOPEC, E. I. du Pont De Nemours and Co, Exxon Mobil, LyondellBasell Industries, Royal Dutch Shell, and SABIC
May 09, 2024 05:17 ET
|
Research and Markets
Dublin, May 09, 2024 (GLOBE NEWSWIRE) -- The "Ethylene - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Ethylene Market to Reach 406.5 Million...
Los datos del ensayo de fase 2 sobre ERLEADA®▼(apalutamide) más terapia de privación androgénica tras prostatectomía radical en pacientes con cáncer de próstata localizado de alto riesgo muestran una tasa de recidiva libre de efectos bioquímicos del 100 por ciento más de dos años después de la cirugía
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
El estudio destaca la oportunidad de intensificar el tratamiento en esta población, ya que aproximadamente el 50 por ciento de los pacientes con cáncer de próstata localizado de alto riesgo (CPAR)...
Phase-II-Daten für ERLEADA®▼(apalutamide) plus Androgendeprivationstherapie nach radikaler Prostatektomie bei Patienten mit lokal begrenztem Hochrisiko-Prostatakrebs zeigen 100 prozentige biochemische Rezidivfreiheit mehr als zwei Jahre nach der Operation
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Die Studie unterstreicht die Möglichkeit einer Intensivierung der Behandlung in dieser Patientengruppe, da bei etwa 50 Prozent der Patienten mit lokalisiertem Hochrisiko-Prostatakrebs (High-risk...
Dati della Fase 2 di ERLEADA®▼(apalutamide) più trattamento di deprivazione androgenica in seguito a prostatectomia radicale in pazienti affetti da tumore della prostata localizzato ad alto rischio mostrano un tasso del 100 percento di assenza di recidiva biochimica più di due anni dopo l'intervento
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Lo studio evidenzia l'opportunità di intensificare il trattamento in tale popolazione poiché approssimativamente il 50 percento di pazienti con tumore della prostata localizzato ad alto rischio...
Données de phase 2 pour ERLEADA®▼(apalutamide) en association avec un traitement par privation androgénique après une prostatectomie radicale chez des patients atteints d’un cancer de la prostate localisé à haut risque : un taux de survie sans récidive biochimique de 100 pour cent plus de deux ans après l’intervention chirurgicale
May 09, 2024 05:11 ET
|
Janssen Cilag International NV
L’étude met en évidence la possibilité d’intensifier le traitement pour cette population, puisque près de 50 pour cent des patients atteints d’un cancer de la prostate localisé à haut risque (CPLHR)...
- May 09, 2024 05:35 ET Global Outdoor Furniture Business Analysis Report 2024-2030: Innovations Blur the Difference between Outdoor and Indoor Furniture, Innovative Weather Resistant Materials & Fabrics Fuel Demand
- May 09, 2024 05:23 ET Global Antimicrobial Coatings Industry Research 2024-2030: A Powerful Solution for Biomedical Applications, Spiraling Popularity for Medical Devices, Revival in Construction Spurs Growth